Associations of blood-based biomarkers of neurodegenerative diseases with mortality, cardio- and cerebrovascular events in persons with chronic coronary syndrome.

Lohner, Valerie; Mons, Ute; Schöttker, Ben; Perneczky, Robert; Brenner, Hermann; Perna, Laura

doi:10.1016/j.exger.2025.112684

Items
Marc 21

001			276341
005			20250216000753.0
024	7	_	\|a 10.1016/j.exger.2025.112684 \|2 doi
024	7	_	\|a pmid:39824235 \|2 pmid
024	7	_	\|a 0531-5565 \|2 ISSN
024	7	_	\|a 1873-6815 \|2 ISSN
024	7	_	\|a altmetric:173429399 \|2 altmetric
037	_	_	\|a DZNE-2025-00289
041	_	_	\|a English
082	_	_	\|a 610
100	1	_	\|a Lohner, Valerie \|b 0
245	_	_	\|a Associations of blood-based biomarkers of neurodegenerative diseases with mortality, cardio- and cerebrovascular events in persons with chronic coronary syndrome.
260	_	_	\|a Amsterdam [u.a.] \|c 2025 \|b Elsevier Science
336	7	_	\|a article \|2 DRIVER
336	7	_	\|a Output Types/Journal article \|2 DataCite
336	7	_	\|a Journal Article \|b journal \|m journal \|0 PUB:(DE-HGF)16 \|s 1739354471_25680 \|2 PUB:(DE-HGF)
336	7	_	\|a ARTICLE \|2 BibTeX
336	7	_	\|a JOURNAL_ARTICLE \|2 ORCID
336	7	_	\|a Journal Article \|0 0 \|2 EndNote
520	_	_	\|a In light of growing evidence highlighting interactions between cardiac and brain health, we investigated associations of biomarkers of neurodegenerative diseases with adverse outcomes (all-cause and cardiovascular mortality, major cardiovascular events, and stroke) in persons with chronic coronary syndrome (CCS).We used data from a cohort of persons with CCS for whom major adverse events were recorded over a follow-up of 20 years. We measured biomarkers of neurodegenerative diseases in baseline blood samples, using the Single-Molecule Array Technology on a HD-1 Analyzer. These include biomarkers of neuronal (neurofilament light chain (NfL) (n = 379)) and glial neurodegeneration (glial fibrillary acidic protein (GFAP) (n = 379)), and Alzheimer's disease pathology (phosphorylated tau181 (n = 379), total tau (n = 377), and amyloid β (Aβ40, Aβ42, Aβ42/Aβ40) (n = 377)). We applied Cox-proportional hazards models to evaluate associations of these biomarkers with adverse outcomes, adjusting for covariates and exploring interactions with apolipoprotein E (ApoE) ε4 genotype.Participants with higher NfL levels had increased rates of all-cause and cardiovascular mortality (Hazard ratio per increase by one standard deviation (95 % confidence interval): all-cause mortality: 1.36 (1.10-1.68); cardiovascular mortality: 1.42 (1.05-1.93)). The Aβ40/Aβ42-ratio was linked to incident stroke (0.72 (0.52-1.00)). Associations of GFAP with all-cause mortality and incident stroke were depending on ApoE ε4 genotype. The other biomarkers were not significantly associated with the studied outcomes.In persons with CSS, NfL and the Aβ40/Aβ42-ratio were related to mortality and incident stroke, respectively, whereas associations of GFAP with adverse outcomes varied by ApoE genotype. These biomarkers might play a role in linking aging, cardiovascular and neurodegenerative diseases.
536	_	_	\|a 353 - Clinical and Health Care Research (POF4-353) \|0 G:(DE-HGF)POF4-353 \|c POF4-353 \|f POF IV \|x 0
588	_	_	\|a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650	_	7	\|a Blood-based biomarkers of neurodegenerative diseases \|2 Other
650	_	7	\|a Cerebrovascular events \|2 Other
650	_	7	\|a Chronic coronary syndrome \|2 Other
650	_	7	\|a Coronary heart disease \|2 Other
650	_	7	\|a Epidemiology \|2 Other
650	_	7	\|a Major cardiovascular events \|2 Other
650	_	7	\|a Mortality \|2 Other
650	_	7	\|a Biomarkers \|2 NLM Chemicals
650	_	7	\|a Amyloid beta-Peptides \|2 NLM Chemicals
650	_	7	\|a tau Proteins \|2 NLM Chemicals
650	_	7	\|a Glial Fibrillary Acidic Protein \|2 NLM Chemicals
650	_	7	\|a neurofilament protein L \|2 NLM Chemicals
650	_	7	\|a GFAP protein, human \|2 NLM Chemicals
650	_	7	\|a Apolipoprotein E4 \|2 NLM Chemicals
650	_	7	\|a Neurofilament Proteins \|2 NLM Chemicals
650	_	2	\|a Humans \|2 MeSH
650	_	2	\|a Biomarkers: blood \|2 MeSH
650	_	2	\|a Female \|2 MeSH
650	_	2	\|a Male \|2 MeSH
650	_	2	\|a Aged \|2 MeSH
650	_	2	\|a Middle Aged \|2 MeSH
650	_	2	\|a Amyloid beta-Peptides: blood \|2 MeSH
650	_	2	\|a Neurodegenerative Diseases: blood \|2 MeSH
650	_	2	\|a Neurodegenerative Diseases: mortality \|2 MeSH
650	_	2	\|a tau Proteins: blood \|2 MeSH
650	_	2	\|a Glial Fibrillary Acidic Protein: blood \|2 MeSH
650	_	2	\|a Stroke: blood \|2 MeSH
650	_	2	\|a Stroke: mortality \|2 MeSH
650	_	2	\|a Cardiovascular Diseases: mortality \|2 MeSH
650	_	2	\|a Cardiovascular Diseases: blood \|2 MeSH
650	_	2	\|a Proportional Hazards Models \|2 MeSH
650	_	2	\|a Apolipoprotein E4: genetics \|2 MeSH
650	_	2	\|a Neurofilament Proteins \|2 MeSH
700	1	_	\|a Perna, Laura \|b 1
700	1	_	\|a Schöttker, Ben \|b 2
700	1	_	\|a Perneczky, Robert \|0 P:(DE-2719)2812234 \|b 3 \|u dzne
700	1	_	\|a Brenner, Hermann \|b 4
700	1	_	\|a Mons, Ute \|b 5
773	_	_	\|a 10.1016/j.exger.2025.112684 \|g Vol. 200, p. 112684 - \|0 PERI:(DE-600)2005397-6 \|p 112684 \|t Experimental gerontology \|v 200 \|y 2025 \|x 0531-5565
856	4	_	\|u https://pub.dzne.de/record/276341/files/DZNE-2025-00289%20SUP.pdf
856	4	_	\|y OpenAccess \|u https://pub.dzne.de/record/276341/files/DZNE-2025-00289.pdf
856	4	_	\|x pdfa \|u https://pub.dzne.de/record/276341/files/DZNE-2025-00289%20SUP.pdf?subformat=pdfa
856	4	_	\|y OpenAccess \|x pdfa \|u https://pub.dzne.de/record/276341/files/DZNE-2025-00289.pdf?subformat=pdfa
909	C	O	\|o oai:pub.dzne.de:276341 \|p openaire \|p open_access \|p VDB \|p driver \|p dnbdelivery
910	1	_	\|a Deutsches Zentrum für Neurodegenerative Erkrankungen \|0 I:(DE-588)1065079516 \|k DZNE \|b 3 \|6 P:(DE-2719)2812234
913	1	_	\|a DE-HGF \|b Gesundheit \|l Neurodegenerative Diseases \|1 G:(DE-HGF)POF4-350 \|0 G:(DE-HGF)POF4-353 \|3 G:(DE-HGF)POF4 \|2 G:(DE-HGF)POF4-300 \|4 G:(DE-HGF)POF \|v Clinical and Health Care Research \|x 0
914	1	_	\|y 2025
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0200 \|2 StatID \|b SCOPUS \|d 2025-01-02
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0160 \|2 StatID \|b Essential Science Indicators \|d 2025-01-02
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)1050 \|2 StatID \|b BIOSIS Previews \|d 2025-01-02
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)1190 \|2 StatID \|b Biological Abstracts \|d 2025-01-02
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0600 \|2 StatID \|b Ebsco Academic Search \|d 2025-01-02
915	_	_	\|a WoS \|0 StatID:(DE-HGF)0113 \|2 StatID \|b Science Citation Index Expanded \|d 2025-01-02
915	_	_	\|a Creative Commons Attribution-NonCommercial CC BY-NC 4.0 \|0 LIC:(DE-HGF)CCBYNC4 \|2 HGFVOC
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0501 \|2 StatID \|b DOAJ Seal \|d 2023-06-13T12:49:31Z
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0500 \|2 StatID \|b DOAJ \|d 2023-06-13T12:49:31Z
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)1030 \|2 StatID \|b Current Contents - Life Sciences \|d 2025-01-02
915	_	_	\|a Fees \|0 StatID:(DE-HGF)0700 \|2 StatID \|d 2025-01-02
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0150 \|2 StatID \|b Web of Science Core Collection \|d 2025-01-02
915	_	_	\|a OpenAccess \|0 StatID:(DE-HGF)0510 \|2 StatID
915	_	_	\|a Peer Review \|0 StatID:(DE-HGF)0030 \|2 StatID \|b ASC \|d 2025-01-02
915	_	_	\|a Article Processing Charges \|0 StatID:(DE-HGF)0561 \|2 StatID \|d 2025-01-02
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0300 \|2 StatID \|b Medline \|d 2025-01-02
915	_	_	\|a Nationallizenz \|0 StatID:(DE-HGF)0420 \|2 StatID \|d 2025-01-02 \|w ger
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0199 \|2 StatID \|b Clarivate Analytics Master Journal List \|d 2025-01-02
920	1	_	\|0 I:(DE-2719)5000022 \|k AG Dichgans \|l Vascular Cognitive Impairment & Post-Stroke Dementia \|x 0
980	_	_	\|a journal
980	_	_	\|a VDB
980	_	_	\|a UNRESTRICTED
980	_	_	\|a I:(DE-2719)5000022
980	1	_	\|a FullTexts

Library	Collection	CLSMajor	CLSMinor	Language	Author

Marc 21

guest :: login DZNEPUB
		Search		Submit		Personalize Your alerts Your baskets Your searches		Help